Temporary iridium-192 implant in the management of carcinoma of the prostate.
The controversy about the treatment of carcinoma of the prostate has increased in the last decade, with most urologists favoring radical prostatectomy rather than primary irradiation. Several reports of persistent tumors in 50% to 90% of patients after external irradiation and permanent iodine-125 implantation of the prostate have been disturbing. From July 1977 to December 1985, 200 patients with adenocarcinoma of the prostate were treated by combining bilateral pelvic lymphadenectomy and temporary interstitial iridium-192 implantation of the prostate, followed by external irradiation. Seventy-four (36%) patients underwent biopsies of the prostate 4 months to 2 years after completion of the irradiation. Only 12 (16%) patients had persistent tumors. Complications were minimized subsequently by dose modifications.
Syed
A M
AM
Department of Radiation Oncology, Long Beach Memorial Medical Center, CA 90801.
Puthawala
A
A
Austin
P
P
Cherlow
J
J
Perley
J
J
Tansey
L
L
Shanberg
A
A
Sawyer
D
D
Baghdassarian
R
R
Wachs
B
B
D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D006801:Humans; D007496:Iridium Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D007496:Iridium Radioisotopes